Blue Cross Blue Shield

The tests have received coverage decisions from a number of Blue Cross Blue Shield plans this year including ones in California and New Jersey.

The payor published positive medical policy coverage for the ThyGenX and ThyraMir assays for thyroid nodules deemed indeterminate by standard cytopathological analysis.

Interpace said that its two thyroid tests are now covered for over 280 million patients nationwide including Medicare, Medicare Advantage, and national and regional health plans.

This is Biocept's third BCBS contract and enables cancer patients to access the company's testing services in network under their Wellmark health plans.

The NGS-based test, which was approved by the FDA in June, will be now available to the insurers' members, who have non-small cell lung cancer, in four states.

The partners will collaborate on clinical studies aimed at driving health plan coverage for molecular diagnostic products.

The company announced positive coverage decisions from Palmetto GBA, 14 BCBS plans, and Aetna.

The company touted the recent spate of positive payor coverage decisions it has seen for its ConfirmMDx and SelectMDx prostate cancer tests.

The positive insurance coverage decision for ConfirmMDx is one of several the company has received in recent months.

CareFirst covers more than 3 million patients in Maryland, Washington DC, and Virginia, and is one several payors to recently issue a coverage decision for Vermillion.

Pages

An Australian-led team has generated a draft genome assembly of the invasive cane toad in hopes it will help in population control, the Sydney Morning Herald reports.

The New York Times reports that the US Department of Defense has implemented about half the recommendations made to improve safe handling of dangerous agents.

In PLOS this week: approach for teasing out archaic introgression in human genomes, immune transcription features in HCV infection, and more.

Stat News reports that Maryland is promoting itself to the biotech industry with a mobile billboard.